Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

Vigabatrin 500 MG Oral Tablet [Sabril]

Known as: Sabril 500 MG Oral Tablet, VIGABATRIN 500 mg ORAL TABLET, FILM COATED [SABRIL] 
National Institutes of Health

Related topics

Related topics

10 relations
Magnesium stearateOral TabletPolyethylene GlycolsPovidone
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Medication Utilization Patterns 90 Days Before Initiation of Treatment with Repository Corticotropin Injection in Patients with Infantile Spasms
Introduction Infantile spasms (IS) is a rare and devastating form of early childhood epilepsy. Two drugs are approved in the… 
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
2016
2016
Sabril® registry 5-year results: Characteristics of adult patients treated with vigabatrin
2016
2016
Which children receive vigabatrin? Characteristics of pediatric patients enrolled in the mandatory FDA registry
Vigabatrin (Sabril®) is an antiepileptic drug (AED) currently indicated in the US as a monotherapy for patients 1month to 2years… 
2012
2012
PND44 Cost-Utility Analysis and Cost-Minimisation Analysis of Sabril® (Vigabatrin) in Drug-Resistant Epilepsy From Payer's Perspective in Poland
2011
2011
Screening for vigabatrin (Sabril®) retinal toxicity in children
  • S. Brodie
  • Ophthalmic genetics
  • 2011
  • Corpus ID: 10154118
Vigabatrin (Sabril®) is used as a drug of last resort in the treatment of refractory seizures. It is associated with a high risk… 
Review
2004
Review
2004
A cost-utility analysis of adjunctive treatment with newer antiepileptic drugs in the UK
Summary A recent review found that economic assessment of epilepsy treatment relies largely on hypothetical modelling of outcomes… 
2000
2000
Der derzeitige Stellenwert von Vigabatrin (Sabril®) in der Epilepsiebehandlung - Ergebnisse einer Konsenskonferenz*
1997
1997
Obstructive sleep apnoea following rapid weight gain secondary to treatment with vigabatrin (Sabril®)
1997
1997
Multicentre clinical evaluation of vigabatrin (Sabril®) in mild to moderate partial epilepsies
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
1997
1997
P-2-203 Analysis of the efficacy of vigabatrin (Sabril®) in traumatic epilepsy
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE